SEC Comment Letter 0000000000-22-013355 to PURPLE BIOTECH LTD. (PPBT)
PURPLE BIOTECH LTD.
Date: Dec. 12, 2022 · CIK: 0001614744 · Accession: 0000000000-22-013355
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268710
Letter
United States securities and exchange commission logo December 12, 2022 Gil Efron Chief Executive Officer Purple Biotech Ltd. 4 Oppenheimer Street Science Park Rehovot 7670104, Israel Re:Purple Biotech Ltd. Registration Statement on Form F-3 Filed December 8, 2022 File No. 333-268710 Dear Gil Efron: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at 202-551-5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jayun Koo, Esq.
Show Raw Text
United States securities and exchange commission logo
December 12, 2022
Gil Efron
Chief Executive Officer
Purple Biotech Ltd.
4 Oppenheimer Street
Science Park
Rehovot 7670104, Israel
Re:Purple Biotech Ltd.
Registration Statement on Form F-3
Filed December 8, 2022
File No. 333-268710
Dear Gil Efron:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at 202-551-5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Jayun Koo, Esq.